Clinical Evaluation of a Multifocal Contact Lens on Symptomatic Patients

This study has been completed.
Sponsor:
Collaborator:
Visioncare Research Ltd.
Information provided by:
Vistakon
ClinicalTrials.gov Identifier:
NCT01016652
First received: November 18, 2009
Last updated: January 21, 2010
Last verified: January 2010
  Purpose

The purpose of this study is to evaluate the effect of a multi-focal contact lens on symptomatic patients.


Condition Intervention
Presbyopia
Device: Etafilcon A Multifocal Contact Lens
Device: Etafilcon A Contact Lens

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Vistakon:

Primary Outcome Measures:
  • Subjective Vision [ Time Frame: After two weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Amplitude of Accommodation [ Time Frame: After two weeks ] [ Designated as safety issue: No ]

Enrollment: 51
Study Start Date: October 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Etafilcon A Multifocal Device: Etafilcon A Multifocal Contact Lens
Comparison of 2 soft contact lens designs.
Active Comparator: Etafilicon A Device: Etafilcon A Contact Lens
Comparison of 2 soft contact lens designs.

  Eligibility

Ages Eligible for Study:   35 Years to 47 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • To have signed an informed consent form (documented by the investigator in the Case Report Form [CRF]).
  • Be existing daily wear spherical single-vision soft CL wearers (no extended wear in the last 3 months, but silicone hydrogels in daily wear are allowed).
  • Between 35 and 47 years of age (inclusive).
  • Have a CL spherical distance requirement between -1.00D and -6.00D (-6.50D refractive) in both eyes.
  • Refractive astigmatism of 0.75D or less in both eyes.
  • Visual symptoms associated with near vision
  • Be correctable to a visual acuity of 6/9 (20/30) or better in each eye.
  • Have normal eyes with no evidence of abnormality or disease. For the purpose of this study a normal eye is defined as one having:

    1. No amblyopia.
    2. No evidence of lid abnormality or infection.
    3. No conjunctival abnormality or infection.
    4. No clinically significant slit lamp findings (i.e. stromal haze, staining, scarring, Vascularization, infiltrates or abnormal opacities).
    5. No other active ocular disease.

Exclusion Criteria:

  • Monovision user or multifocal CL wearer.
  • Regular user of reading spectacles (i.e. daily usage).
  • Requires concurrent ocular medication.
  • Clinically significant (Grade 3 or 4) corneal stromal haze, corneal Vascularization, tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any other abnormality of the cornea that would contraindicate CL wear.
  • Corneal staining Grade 3 in more than two regions.
  • Has had any anterior ocular surgery. Has had any other ocular surgery or injury within 8 weeks immediately prior to enrollment for this study.
  • Pre-existing ocular irritation that would preclude CL fitting.
  • Keratoconus or other corneal irregularity.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01016652

Locations
United States, Arkansas
North Little Rock, Arkansas, United States
United States, Missouri
Blue Springs, Missouri, United States
Lake Ozark, Missouri, United States
United States, Ohio
Warren, Ohio, United States
United States, Pennsylvania
Kittanning, Pennsylvania, United States
United States, Rhode Island
Warwick, Rhode Island, United States
United States, South Dakota
Chamberlain, South Dakota, United States
United States, Vermont
Burlington, Vermont, United States
Sponsors and Collaborators
Vistakon
Visioncare Research Ltd.
  More Information

No publications provided

Responsible Party: Tom Karkkainen, Johnson & Johnson Vision Care, Inc.
ClinicalTrials.gov Identifier: NCT01016652     History of Changes
Other Study ID Numbers: CR-4558, VMFL-511
Study First Received: November 18, 2009
Last Updated: January 21, 2010
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Presbyopia
Refractive Errors
Eye Diseases

ClinicalTrials.gov processed this record on May 19, 2013